Marovil

Marovil may be available in the countries listed below.

Ingredient matches for Marovil

Cisapride

Cisapride is reported as an ingredient of Marovil in the following countries:

• Chile

International Drug Name Search

Adrenalin SAD

Adrenalin SAD may be available in the countries listed below.

Ingredient matches for Adrenalin SAD

Epinephrine

Epinephrine bitartrate (a derivative of Epinephrine) is reported as an ingredient of Adrenalin SAD in the following countries:

• Denmark

International Drug Name Search

Silol

Silol may be available in the countries listed below.

Ingredient matches for Silol

Dimeticone

Dimeticone is reported as an ingredient of Silol in the following countries:

• Poland

International Drug Name Search

Prilocaine

In some countries, this medicine may only be approved for veterinary use.

In the US, Prilocaine (prilocaine systemic) is a member of the drug class local injectable anesthetics.

US matches:

• Prilocaine Hydrochloride


• Prilocaine Hydrochloride Injection

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

N01BB04

CAS registry number (Chemical Abstracts Service)

0000721-50-6

Chemical Formula

C13-H20-N2-O

Molecular Weight

220

Therapeutic Category

Anesthetic, local

Chemical Name

Propanamide, N-(2-methylphenyl)-2-(propylamino)-

Foreign Names

• Prilocainum (Latin)
• Prilocain (German)
• Prilocaïne (French)
• Prilocaina (Spanish)

Generic Names

• Prilocaina (OS: DCIT)
• Prilocaine (OS: USAN, BAN)
• Prilocaïne (OS: DCF)
• Propitocaine (IS)
• Prilocain (PH: Ph. Eur. 6)
• Prilocaine (PH: BP 2010, USP 32, Ph. Eur. 6)
• Prilocaïne (PH: Ph. Eur. 6)
• Prilocainum (PH: Ph. Eur. 6)
• Prilocaine Hydrochloride (OS: BANM, USAN)
• Propitocaine Hydrochloride (OS: JAN)
• Astra 1512 (IS: Astra)
• L 67 (IS)
• Prilocaïne (chlorhydrate de) (PH: Ph. Eur. 6)
• Prilocaine Hydrochloride (PH: BP 2010, USP 32, Ph. Eur. 6)
• Prilocainhydrochlorid (PH: Ph. Eur. 6)
• Prilocaini hydrochloridum (PH: Ph. Eur. 6)

Brand Names

• Anesderm (Prilocaine and Lidocaine)
  Pierre Fabre, Switzerland; Pierre Fabre Dermatologie, France



• Citanest
  AstraZeneca, Turkey



• Emla (Prilocaine and Lidocaine)
  APP, United States; AstraZeneca, Austria; AstraZeneca, Belgium; AstraZeneca, Bahrain; AstraZeneca, Canada; AstraZeneca, Switzerland; AstraZeneca, Germany; AstraZeneca, Denmark; AstraZeneca, Spain; AstraZeneca, Finland; AstraZeneca, France; AstraZeneca, United Kingdom; AstraZeneca, Indonesia; AstraZeneca, Italy; AstraZeneca, Netherlands; AstraZeneca, Norway; AstraZeneca, New Zealand; AstraZeneca, Oman; AstraZeneca, Peru; Cana, Greece; Dr. Fisher, Netherlands; Euro, Netherlands; Medcor, Netherlands



• EMLA (Prilocaine and Lidocaine)
  AstraZeneca, Sweden



• EmlaPatch (Prilocaine and Lidocaine)
  AstraZeneca, France



• Estesia (Prilocaine and Lidocaine)
  Pharmacore Labs, Indonesia



• Funis (Prilocaine and Lidocaine)
  Target Pharma, Greece



• Lidocaïne Prilocaïne Aguettant (Prilocaine and Lidocaine)
  Aguettant, France



• Lidocaïne Prilocaïne Biogaran (Prilocaine and Lidocaine)
  Biogaran, France



• Oraqix (Prilocaine and Lidocaine)
  Dentsply, Austria; Dentsply, Germany; Dentsply, France; Dentsply, Italy; Dentsply, Norway; Dentsply, United States; Globopharm, Switzerland; Dentsply Ltd.GB, Denmark



• Tapin (Prilocaine and Lidocaine)
  Copyfarm, Denmark; Orifarm, Sweden



• Topla (Prilocaine and Lidocaine)
  Cipla Medpro, South Africa



• Citanest Dental Octapressin (Prilocaine and Felypressin)
  Dentsply, Finland; Dentsply, Iceland; Dentsply, Norway



• Citanest Forte (Prilocaine and Epinephrine)
  Dentsply, United States



• Citanest Octapressin (Prilocaine and Felypressin)
  AstraZeneca, United Arab Emirates; AstraZeneca, Bahrain; AstraZeneca, Egypt; AstraZeneca, Iraq; AstraZeneca, Jordan; AstraZeneca, Kuwait; AstraZeneca, Lebanon; AstraZeneca, Libya; AstraZeneca, Oman; AstraZeneca, Qatar; AstraZeneca, Saudi Arabia; AstraZeneca, Syria; AstraZeneca, Yemen; Dentsply-Sankin, Japan; Dentsply Ltd.GB, Denmark



• Citanest with Octapressin (Prilocaine and Felypressin)
  Dentsply, New Zealand



• Citanest
  AstraZeneca, United Arab Emirates; AstraZeneca, Australia; AstraZeneca, Belgium; AstraZeneca, Bahrain; AstraZeneca, Egypt; AstraZeneca, United Kingdom; AstraZeneca, Georgia; AstraZeneca, Iraq; AstraZeneca, Jordan; AstraZeneca, Kuwait; AstraZeneca, Lebanon; AstraZeneca, Luxembourg; AstraZeneca, Netherlands; AstraZeneca, New Zealand; AstraZeneca, Oman; AstraZeneca, Saudi Arabia; AstraZeneca, Sweden; AstraZeneca, Syria; AstraZeneca, United States; AstraZeneca, Yemen; Dentsply, Australia; Dentsply, Netherlands; Dentsply, United States



• Citanest (Prilocaine and Epinephrine)
  Dentsply-Sankin, Japan



• Citanest (veterinary use)
  AstraZeneca, United Kingdom



• Prilocaine Sintetica
  Sintetica, Switzerland



• Prilocaine (veterinary use)
  Delvet, Australia; Parnell Laboratories, Australia



• Xylonest
  AstraZeneca, Switzerland; AstraZeneca, Germany



• Xylonest mit Adrenalin (Prilocaine and Epinephrine)
  AstraZeneca, Germany



• Xylonest Octapressin (Prilocaine and Felypressin)
  Dentsply, Germany

International Drug Name Search

Glossary

BAN	British Approved Name
BANM	British Approved Name (Modified)
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Phanalgin

Phanalgin may be available in the countries listed below.

Ingredient matches for Phanalgin

Metamizole

Metamizole is reported as an ingredient of Phanalgin in the following countries:

• Israel

International Drug Name Search

Ranicon

Ranicon may be available in the countries listed below.

Ingredient matches for Ranicon

Oxyphencyclimine

Oxyphencyclimine hydrochloride (a derivative of Oxyphencyclimine) is reported as an ingredient of Ranicon in the following countries:

• Bangladesh

International Drug Name Search

Targiniq

Targiniq may be available in the countries listed below.

Ingredient matches for Targiniq

Naloxone

Naloxone hydrochloride (a derivative of Naloxone) is reported as an ingredient of Targiniq in the following countries:

• Sweden

Oxycodone

Oxycodone hydrochloride (a derivative of Oxycodone) is reported as an ingredient of Targiniq in the following countries:

• Sweden

International Drug Name Search

Mycamine

Mycamine is a brand name of micafungin, approved by the FDA in the following formulation(s):

MYCAMINE (micafungin sodium - injectable; iv (infusion))

• 
  Manufacturer: ASTELLAS
  
  Approval date: March 16, 2005
  
  Strength(s): 50MG/VIAL ^[RLD]


• 
  Manufacturer: ASTELLAS
  
  Approval date: June 27, 2006
  
  Strength(s): 100MG/VIAL ^[RLD]

Has a generic version of Mycamine been approved?

No. There is currently no therapeutically equivalent version of Mycamine available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mycamine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Polypeptide compound and a process for preparation thereof
  Patent 5,376,634
  Issued: December 27, 1994
  Inventor(s): Iwamoto; Toshiro & Fujie; Akihiko & Nitta; Kumiko & Tsurumi; Yasuhisa & Shigematsu; Nobuharu & Kasahara; Chiyoshi & Hino; Motohiro & Okuhara; Masakuni & Sakane; Kazuo & Kawabata; Kohji & Ohki; Hidenori
  Assignee(s): Fujisawa Pharmaceutical Co., Ltd.
  A polypeptide compound having antimicrobial activity of the following general formula: ##STR1## wherein R.sup.1 is hydrogen or acyl group, R.sup.2 is hydroxy or acyloxy, R.sup.3 is hydroxysulfonyloxy, and R.sup.4 is hydrogen or carbamoyl, with proviso that R.sup.1 is not palmitoyl, when R.sup.2 is hydroxy, R.sup.3 is hydroxysulfonyloxy and R.sup.4 is carbamoyl, and a pharmaceutically acceptable salt thereof.
  
  Patent expiration dates:
  
  
  • December 27, 2011
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Cyclic hexapeptides having antibiotic activity
  Patent 6,107,458
  Issued: August 22, 2000
  Inventor(s): Ohki; Hidenori & Tomishima; Masaki & Yamada; Akira & Takasugi; Hisashi
  Assignee(s): Fujisawa Pharmaceutical Co., Ltd.
  This invention relates to new polypeptide compounds represented by the following formula (I): ##STR1## wherein R.sup.1 is as defined in the description and pharmaceutically acceptable salt thereof which have antimicrobial activities (especially, antifungal activities), inhibitory activity on .beta.-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.
  
  Patent expiration dates:
  
  
  • March 16, 2019
    
    ✓ 
    Patent use: TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • March 16, 2019
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABCESSES
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Cyclic hexapeptides having antibiotic activity
  Patent 6,265,536
  Issued: July 24, 2001
  Inventor(s): Ohki; Hidenori & Tomishima; Masaki & Yamada; Akira & Takasugi; Hisashi
  Assignee(s): Fujisawa Pharmaceutical Co., Ltd.
  This invention relates to new polypeptide compounds represented by the following formula (I): ##STR1## wherein R.sup.1 is as defined in the description and pharmaceutically acceptable salt thereof which have antimicrobial activities (especially, antifungal activities), inhibitory activity on .beta.-1,3-glucan synthase, to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prophylactic and/or therapeutic treatment of infectious diseases including Pneumocystis carinii infection (e.g. Pneumocystis carinii pneumonia) in a human being or an animal.
  
  Patent expiration dates:
  
  
  • September 29, 2015
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABCESSES
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 29, 2015
    
    ✓ 
    Patent use: TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Stabilized pharmaceutical composition in lyophilized form
  Patent 6,774,104
  Issued: August 10, 2004
  Inventor(s): Seiji; Sawai & Akihiro; Kasai & Kazumi; Otomo
  Assignee(s): Fujisawa Pharmaceutical Co., Ltd.
  A stabilized pharmaceutical composition in lyophilized form comprising: a cyclic polypeptide compound represented by the general formula (I): wherein R1 is a hydrogen atom or an acyl group and R2 and R3 are, the same or different, a hydrogen atom or a hydroxyl group, or a salt thereof and the stabilizer.
  
  Patent expiration dates:
  
  
  • January 8, 2021
    
    ✓ 
    Patent use: TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS
    ✓ 
    Drug product
  
  
  
  • January 8, 2021
    
    ✓ 
    Patent use: TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABCESSES
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • January 22, 2011 - TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONIS AND ABSCESSES
  
  

See also...

• Mycamine Consumer Information (Drugs.com)
• Mycamine Consumer Information (Wolters Kluwer)
• Mycamine Consumer Information (Cerner Multum)
• Mycamine Advanced Consumer Information (Micromedex)
• Mycamine AHFS DI Monographs (ASHP)
• Micafungin Consumer Information (Wolters Kluwer)
• Micafungin Consumer Information (Cerner Multum)
• Micafungin Intravenous Advanced Consumer Information (Micromedex)
• Micafungin Sodium AHFS DI Monographs (ASHP)

Plumarol

Plumarol may be available in the countries listed below.

Ingredient matches for Plumarol

Miglitol

Miglitol is reported as an ingredient of Plumarol in the following countries:

• Spain

International Drug Name Search

Furosemid Genericon

Furosemid Genericon may be available in the countries listed below.

Ingredient matches for Furosemid Genericon

Furosemide

Furosemide is reported as an ingredient of Furosemid Genericon in the following countries:

• Austria

Furosemide sodium (a derivative of Furosemide) is reported as an ingredient of Furosemid Genericon in the following countries:

• Austria

International Drug Name Search

Dolamin

Dolamin may be available in the countries listed below.

Ingredient matches for Dolamin

Clonixin

Clonixin lysine salt (a derivative of Clonixin) is reported as an ingredient of Dolamin in the following countries:

• Brazil

International Drug Name Search